OTCMKTS:KALTF Claritas Pharmaceuticals - KALTF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Claritas Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.01 0.00 (0.00%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.01▼$0.0150-Day Range$0.01▼$0.0852-Week Range$0.03▼$1.36VolumeN/AAverage Volume9,705 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlinesShort Interest About Claritas Pharmaceuticals (OTCMKTS:KALTF) StockClaritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. It also offers development programs for bone fracture healing, osteogenesis imperfecta, osteoporosis, and osteoporosis in Prader-Willi syndrome. The company was founded by Seth Yakatan on October 15, 2004 and is headquartered in San Rafael, CA.Read More Receive KALTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Claritas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KALTF Stock News HeadlinesMarch 17, 2023 | marketwatch.comGeneric Drugs Market Share, Segmentation and Forecast 2023-2028February 14, 2023 | marketwatch.com2023 Pharmaceutical CDMO Services Market Segmentation and Targeting: Strategies for Success Forecast till 2028March 22, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …February 13, 2023 | marketwatch.com2023 Mifepristone Market Segmentation and Targeting: Strategies for Success Forecast till 2028January 19, 2023 | marketwatch.comRadioimmunotherapy Treatment Market Geographical Segmentation By Forecast Revenue 2023-2028January 12, 2023 | finance.yahoo.comClaritas Pharmaceuticals, Inc. (CLAZF)January 5, 2023 | marketwatch.comOnline Pharmaceuticals Market Evolution Segmentation and Insight of Trends 2023 to 2028 with Top Countries DataNovember 30, 2022 | marketwatch.comAnalgesics Market Global Investor, Latest Trends, Industry Growth, Size, Segmentation, Future Demands, by Regional Forecast to 2028March 22, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …September 30, 2022 | marketwatch.comPharmaceutical Sachet Market In 2022 : Industry Growth, Top Players, Segmentation and Forecast to 2028 with Top Countries DataSeptember 22, 2022 | finance.yahoo.comNew Claritas Report Reveals that the U.S. Hispanic Population Grew 89% Since 2000 – and Will Exceed 74 Million Consumers by 2028September 13, 2022 | reuters.comClaritas Pharmaceuticals IncMay 11, 2022 | investing.comClaritas Pharmaceuticals Inc (CLAS)March 12, 2022 | benzinga.comKaya Now Appoints Stormy Simon As A Director Of The BoardFebruary 22, 2022 | finance.yahoo.comClaritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of FinancingFebruary 9, 2022 | finance.yahoo.comClaritas Anticipates Response from Australian Ethics Committee by February 18, 2022January 26, 2022 | finance.yahoo.comClaritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina PartnersJanuary 17, 2022 | finance.yahoo.comClaritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe BurnsJanuary 17, 2022 | finance.yahoo.comClaritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina PartnersJanuary 12, 2022 | seekingalpha.comClaritas Pharmaceuticals signs $5M equity financing dealJanuary 12, 2022 | finance.yahoo.comClaritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.December 22, 2021 | finance.yahoo.comClaritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in NewbornsDecember 21, 2021 | finance.yahoo.comClaritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary DiseaseDecember 20, 2021 | finance.yahoo.comClaritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of SepsisNovember 18, 2021 | finance.yahoo.comClaritas Provides Update Regarding Phase 1 Clinical StudyNovember 4, 2021 | finance.yahoo.comClaritas Announces Engagement of B. Riley Securities as Sponsor for the Company’s Planned Up-Listing of its Securities to the OTCQBOctober 19, 2021 | finance.yahoo.comClaritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLCSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KALTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Claritas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KALTF Company Calendar Last Earnings11/29/2013Today3/22/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:KALTF Previous SymbolOTCMKTS:QUEZF CUSIPN/A CIKN/A Webkalytera.co Phone(888) 861-2008FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesRobert Edward FarrellChairman, President & Chief Executive OfficerVictoria Diana RudmanChief Financial Officer, Secretary & TreasurerNedira FrenkelDirector-Business DevelopmentKey Competitors3SBioOTCMKTS:TRSBFAbattis BioceuticalsOTCMKTS:ATTBFAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFAinosNASDAQ:AIMDWView All Competitors KALTF Stock - Frequently Asked Questions How have KALTF shares performed in 2023? Claritas Pharmaceuticals' stock was trading at $0.01 at the beginning of the year. Since then, KALTF shares have increased by 0.0% and is now trading at $0.01. View the best growth stocks for 2023 here. How were Claritas Pharmaceuticals' earnings last quarter? Claritas Pharmaceuticals, Inc. (OTCMKTS:KALTF) issued its quarterly earnings results on Friday, November, 29th. The company reported ($0.40) earnings per share for the quarter. When did Claritas Pharmaceuticals' stock split? Claritas Pharmaceuticals's stock reverse split before market open on Friday, July 23rd 2021. The 1-20 reverse split was announced on Friday, July 23rd 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 23rd 2021. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Claritas Pharmaceuticals' stock symbol? Claritas Pharmaceuticals trades on the OTCMKTS under the ticker symbol "KALTF." How do I buy shares of Claritas Pharmaceuticals? Shares of KALTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Claritas Pharmaceuticals' stock price today? One share of KALTF stock can currently be purchased for approximately $0.01. How can I contact Claritas Pharmaceuticals? Claritas Pharmaceuticals' mailing address is 4040 Civic Center Drive, San Rafael, CA 94903. The official website for the company is kalytera.co. The company can be reached via phone at (888) 861-2008. This page (OTCMKTS:KALTF) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.